Altaris to acquire US and UK cell therapy business from WuXi AppTec.

Altaris, a US-based investment firm, agreed to acquire US and UK cell therapy business from WuXi AppTec, a global pharmaceutical, biopharmaceutical, and medical device company. Financial terms were not disclosed. This transaction builds on Altaris’ strategic initiative in the cell therapy sector, which is focused on delivering life-changing therapies to patients at scale. With a 20+ year track record as an owner of healthcare companies, including 11 manufacturers in the pharmaceutical industry, Altaris is well-positioned to support Advanced Therapies over its next phase of growth.